EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

Luying Xiong, Xueting Wang, Yuan Wang, Wei Yu, Yanzi Zhou, Xiaohui Chi, Tingting Xiao, Yonghong Xiao iD

WIREs Mechanisms of Disease · 2022-11 · 14 (6)

DOI: 10.1002/wsbm.1571 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Mechanisms of Disease, online erschienen am 26.07.2022. Verfasst von Luying Xiong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Di…. Hauptthemen laut MEDLINE: Ceftazidime, Anti-Bacterial Agents. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal infections in adults, as well as to treat patients infected with Carbapenem‐resistant Enterobacteriaceae (CRE) susceptible to CAZ/AVI. However, increased clinical application of CAZ/AVI has resulted in the development of resistant strains. Mechanisms of resistance in most of these strains have been attributed to bla KPC mutations, which lead to amino acid substitutions in β‐lactamase and changes in gene expression. Resistance to CAZ/AVI is also associated with reduced expression and loss of outer membrane proteins or overexpression of efflux pumps. In this review, the prevalence of CAZ/AVI‐resistance bacteria, resistance mechanisms, and selection of detection methods of CAZ/AVI are demonstrated, aiming to provide scientific evidence for the clinical prevention and treatment of CAZ/AVI resistant strains, and provide guidance for the development of new drugs. This article is categorized under: Infectious Diseases > Molecular and Cellular Physiology

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAnti-Bacterial AgentsAdultHumansMicrobial Sensitivity Testsbeta-LactamasesAzabicyclo Compounds

Stichwörter der Autor:innen

ceftazidime/avibactamefflux pumpouter membrane proteinresistance mechanismβ-lactamase

Substanzen

CeftazidimeAnti-Bacterial Agentsbeta-LactamasesavibactamAzabicyclo Compounds

Autor:innen und Institutionen

  • Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang U…
  • Jinan Microecological Biomedicine Shandong Laboratory, Jinan, China.

ORCID-Profile: Yonghong Xiao

Zitieren

APA

Xiong, L., Wang, X., Wang, Y., Yu, W., Zhou, Y., Chi, X., Xiao, T., & Xiao, Y. (2022). Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam. WIREs Mechanisms of Disease, 14(6). https://doi.org/10.1002/wsbm.1571

Vancouver

Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, et al. Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam. WIREs Mechanisms of Disease. 2022;14(6). doi:10.1002/wsbm.1571

BibTeX
@article{Xiong2022,
  author = {Xiong, Luying and Wang, Xueting and Wang, Yuan and Yu, Wei and Zhou, Yanzi and Chi, Xiaohui and Xiao, Tingting and Xiao, Yonghong},
  title = {Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam},
  journal = {WIREs Mechanisms of Disease},
  year = {2022},
  volume = {14},
  number = {6},
  doi = {10.1002/wsbm.1571}
}
Kostenlos starten →